AU2001239832A1 - Compositions and methods for the early diagnosis of ovarian cancer - Google Patents

Compositions and methods for the early diagnosis of ovarian cancer

Info

Publication number
AU2001239832A1
AU2001239832A1 AU2001239832A AU2001239832A AU2001239832A1 AU 2001239832 A1 AU2001239832 A1 AU 2001239832A1 AU 2001239832 A AU2001239832 A AU 2001239832A AU 2001239832 A AU2001239832 A AU 2001239832A AU 2001239832 A1 AU2001239832 A1 AU 2001239832A1
Authority
AU
Australia
Prior art keywords
compositions
methods
ovarian cancer
early diagnosis
diagnosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001239832A
Other versions
AU2001239832B2 (en
Inventor
Timothy J. O'brien
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Arkansas
Original Assignee
The Board Of Trustees Of The University Of Arkansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US09/510,738 priority Critical patent/US6268165B1/en
Priority to US09/510,738 priority
Application filed by The Board Of Trustees Of The University Of Arkansas filed Critical The Board Of Trustees Of The University Of Arkansas
Priority to PCT/US2001/005703 priority patent/WO2001062271A1/en
Publication of AU2001239832A1 publication Critical patent/AU2001239832A1/en
Application granted granted Critical
Publication of AU2001239832B2 publication Critical patent/AU2001239832B2/en
Application status is Ceased legal-status Critical
Anticipated expiration legal-status Critical

Links

AU2001239832A 1997-03-19 2001-02-20 Compositions and methods for the early diagnosis of ovarian cancer Ceased AU2001239832B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US09/510,738 US6268165B1 (en) 1997-03-19 2000-02-22 Methods for the early diagnosis of ovarian cancer
US09/510,738 2000-02-22
PCT/US2001/005703 WO2001062271A1 (en) 2000-02-22 2001-02-20 Compositions and methods for the early diagnosis of ovarian cancer

Publications (2)

Publication Number Publication Date
AU2001239832A1 true AU2001239832A1 (en) 2001-11-15
AU2001239832B2 AU2001239832B2 (en) 2004-09-30

Family

ID=24031976

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001239832A Ceased AU2001239832B2 (en) 1997-03-19 2001-02-20 Compositions and methods for the early diagnosis of ovarian cancer
AU3983201A Pending AU3983201A (en) 1997-03-19 2001-02-20 Compositions and methods for the early diagnosis of ovarian cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU3983201A Pending AU3983201A (en) 1997-03-19 2001-02-20 Compositions and methods for the early diagnosis of ovarian cancer

Country Status (7)

Country Link
US (2) US6268165B1 (en)
EP (1) EP1257287B1 (en)
JP (1) JP2003523524A (en)
AU (2) AU2001239832B2 (en)
CA (1) CA2400703A1 (en)
MX (1) MXPA02008258A (en)
WO (1) WO2001062271A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7795211B2 (en) * 2000-02-22 2010-09-14 Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
CA2426286A1 (en) * 2000-10-27 2002-05-02 Mount Sinai Hospital Method for detecting ovarian cancer based on human kallikrein 6 (hk6)
WO2002059373A2 (en) * 2001-01-23 2002-08-01 Irm, Llc Genes overexpressed in prostate disorders as diagnostic and therapeutic targets
CA2438433A1 (en) * 2001-02-14 2002-08-22 Tularik Inc. Methods for the diagnosis and treatment of tumors employing the hepsin gene
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
US7700293B2 (en) 2001-08-02 2010-04-20 The Regents Of The University Of Michigan Expression profile of prostate cancer
US7332290B2 (en) 2001-08-02 2008-02-19 The Regents Of The University Of Michigan Dectection of AMACR cancer markers in urine
AU2002335640A1 (en) * 2001-08-17 2003-03-03 Affymetrix, Inc. Gleason grade 4/5 prostate cancer genes
AU2003225540A1 (en) * 2002-01-31 2003-09-02 Irm, Llc Hepsin substrates and prodrugs
US20040029151A1 (en) * 2002-04-09 2004-02-12 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
US20050272052A1 (en) * 2002-04-09 2005-12-08 Affymetrix, Inc. Molecular genetic profiling of gleason grades 3 and 4/5 prostate cancer
WO2004009803A2 (en) * 2002-07-23 2004-01-29 Bayer Healthcare Ag Regulation of human hepsin
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
EP2363205A3 (en) 2006-01-11 2014-06-04 Raindance Technologies, Inc. Microfluidic Devices And Methods Of Use In The Formation And Control Of Nanoreactors
US20080014589A1 (en) 2006-05-11 2008-01-17 Link Darren R Microfluidic devices and methods of use thereof
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
ZA200810225B (en) 2006-06-22 2010-03-31 Genentech Inc Methods and compositions for targeting hepsin
WO2008021123A1 (en) 2006-08-07 2008-02-21 President And Fellows Of Harvard College Fluorocarbon emulsion stabilizing surfactants
WO2008097559A2 (en) 2007-02-06 2008-08-14 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008130623A1 (en) 2007-04-19 2008-10-30 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
EP2411148B1 (en) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation of microfluidic droplets
MX2012004647A (en) 2009-10-22 2012-06-19 Genentech Inc Anti-hepsin antibodies and methods using same.
WO2011073283A1 (en) * 2009-12-15 2011-06-23 Technische Universität Dresden A non-invasive method for diagnosis of prostate cancer
EP2986762A4 (en) 2013-04-19 2017-03-15 Raindance Technologies Inc. Digital analyte analysis
EP3392349A1 (en) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Digital analyte analysis
EP2844768B1 (en) 2012-04-30 2019-03-13 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
WO2011161189A1 (en) 2010-06-24 2011-12-29 F. Hoffmann-La Roche Ag Anti-hepsin antibodies and methods of use
EP2622103B1 (en) 2010-09-30 2018-09-12 Raindance Technologies, Inc. Sandwich assays in droplets
US9364803B2 (en) 2011-02-11 2016-06-14 Raindance Technologies, Inc. Methods for forming mixed droplets
US9150852B2 (en) 2011-02-18 2015-10-06 Raindance Technologies, Inc. Compositions and methods for molecular labeling
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
WO2012174569A2 (en) * 2011-06-17 2012-12-20 The Board Of Trustees Of The University Of Arkansas New markers for early diagnosis of ovarian cancer, monitoring during therapy, and new therapy options during and after chematherapy
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP3495817A1 (en) 2012-02-10 2019-06-12 Raindance Technologies, Inc. Molecular diagnostic screening assay

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3654090B1 (en) 1968-09-24 1982-07-20
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv Method for the detection and determination of laagmoleculire compounds and of proteins that can specifically bind these compounds, as well as the test pack.
US4016043A (en) 1975-09-04 1977-04-05 Akzona Incorporated Enzymatic immunological method for the determination of antigens and antibodies
US4683202B1 (en) 1985-03-28 1990-11-27 Cetus Corp
US4683195B1 (en) 1986-01-30 1990-11-27 Cetus Corp
US4981784A (en) 1987-12-02 1991-01-01 The Salk Institute For Biological Studies Retinoic acid receptor method
US5484726A (en) 1990-11-21 1996-01-16 Bristol-Myers Squibb Company Antibodies specific for human stromelysin-3 and a method for detection of stromelysin-3
DE69505076T2 (en) * 1994-07-29 1999-02-25 Teijin Ltd Trypsintyp enzymes, nucleic acid sequence encoding and methods for producing the enzyme
US6294344B1 (en) * 1997-03-19 2001-09-25 The Board Of Trustees Of The University Of Arkansas Methods for the early diagnosis of ovarian cancer
AU6468998A (en) * 1997-03-19 1998-10-12 Board Of Trustees Of The University Of Arkansas, The Compositions and method for the early diagnosis of ovarian cancer

Similar Documents

Publication Publication Date Title
AU763954C (en) Compositions and methods for cancer treatment by selectively inhibiting VEGF
AU2002305450A1 (en) Proteomimetic compounds and methods
AU4205100A (en) Methods and compositions for the treatment of pancreatitis
AU2002314884A1 (en) Fljs as modifiers of the p53 pathway and methods of use
AU2002320264A1 (en) GFATs as modifiers of the p53 pathway and methods of use
AU2002310256A1 (en) Ppp2cs as modifiers of the p53 pathway and methods of use
ZA200206400B (en) Compositions and methods for the therapy and diagnosis of prostate cancer.
MXPA03003151A (en) Methods of diagnosis of prostate cancer, compositions and methods of screening for modulators of prostate cancer.
AU2001280229A1 (en) Novel thiourea derivatives and the pharmaceutical compositions containing the same
AU2002336539A1 (en) Sunscreen compositions
AU2002324381A1 (en) The production of soluble keratin derivatives
EP1515982A4 (en) Compositions and methods for the therapy and diagnosis of prostate cancer
SG115506A1 (en) Stabilized tetrazolium-phenazine reagent compositions and methods for using the same
AU6918700A (en) Pharmaceutical compositions and methods for reducing the appearance of cellulite
AU2001231172A1 (en) Methods and compositions for generating human monoclonal antibodies
AU2002363005A1 (en) Derivatives of uk-2a
IL156759D0 (en) Kits and pharmaceutical compositions containing epothilone derivatives
AU6100701A (en) Compositions and methods for the therapy and diagnosis of lung cancer
AU2002329826A1 (en) 2-amino-4-heteroarylaminopyrimidine derivatives for use in the treatment of cancer
WO2004030615A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004016225A8 (en) Compositions and methods for the diagnosis and treatment of tumor
WO2004045516A9 (en) Compositions and methods for the diagnosis and treatment of tumor
AU2002246817A1 (en) Thienopyrimidine-based inhibitors of the SRC family
PT1935427T (en) Uses of soluble ctla4 mutant molecules
AU4954901A (en) Compositions and methods for the therapy and diagnosis of prostate cancer